MarketCap
Facebook
X
TelegramAnnual report 2022
added 03-29-2023
Provention Bio EV/EBITDA Ratio 2011-2026 | PRVB
Annual EV/EBITDA Ratio Provention Bio
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| -2.28 | -6.22 | -13.7 | 0.274 | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 0.274 | -13.7 | -5.47 |
EV/EBITDA Ratio of other stocks in the Biotechnology industry
| Issuer | EV/EBITDA Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
FSD Pharma
HUGE
|
-0.271 | - | 5743.5 % | $ 69.7 M |  Canada |
 |
MorphoSys AG
MOR
|
-0.591 | - | 2.43 % | $ 254 M |  Germany |
 |
AgeX Therapeutics
AGE
|
-1.85 | - | -10.17 % | $ 12.2 K |  USA |
 |
I-Mab
IMAB
|
595 | - | - | $ 866 M |  China |
 |
Midatech Pharma plc
MTP
|
0.796 | - | -18.52 % | $ 27.3 M |  Britain |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
10.7 | - | - | $ 40.3 B | USA |
 |
Biophytis SA
BPTS
|
-17.6 | - | -13.47 % | $ 169 M |  France |
 |
Genfit SA
GNFT
|
4.22 K | - | 2.54 % | $ 160 B | France |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-3.42 | - | -1.52 % | $ 24.7 M | USA |
 |
Athira Pharma
ATHA
|
-3.66 | - | - | $ 269 M | USA |
 |
Enlivex Therapeutics Ltd.
ENLV
|
-1 | $ 0.82 | -1.38 % | $ 37.5 M |  Israel |
 |
Exelixis
EXEL
|
18.1 | $ 46.5 | -4.52 % | $ 12.6 B | USA |
 |
Fortress Biotech
FBIO
|
-0.152 | $ 2.47 | -3.18 % | $ 68.9 M | USA |
 |
Heron Therapeutics
HRTX
|
-4.31 | $ 1.24 | -5.73 % | $ 207 M | USA |
 |
InflaRx N.V.
IFRX
|
-1.93 | $ 2.67 | 6.8 % | $ 180 M | Germany |
 |
Ionis Pharmaceuticals
IONS
|
-363 | $ 76.1 | -0.98 % | $ 12.2 B | USA |
 |
BioNTech SE
BNTX
|
4.1 | $ 93.73 | -1.61 % | $ 27.2 B | Germany |
 |
Институт стволовых клеток человека
ISKJ
|
14 | - | - | - |  Russia |
 |
Checkmate Pharmaceuticals
CMPI
|
-0.0315 | - | - | $ 231 M | USA |
 |
Kymera Therapeutics
KYMR
|
-21.5 | $ 86.13 | -0.15 % | $ 7.28 B | USA |
 |
Ligand Pharmaceuticals Incorporated
LGND
|
19.4 | $ 212.22 | -8.74 % | $ 3.88 B | USA |
 |
ACADIA Pharmaceuticals
ACAD
|
-21.1 | $ 22.18 | 3.26 % | $ 3.68 B | USA |
 |
Liquidia Corporation
LQDA
|
-6.02 | $ 42.07 | -0.17 % | $ 3.62 B | USA |
 |
Advaxis
ADXS
|
-82.4 | - | -9.65 % | $ 45.9 M | USA |
 |
Esperion Therapeutics
ESPR
|
-2.15 | $ 3.15 | - | $ 655 M | USA |
 |
Mirum Pharmaceuticals
MIRM
|
2.69 K | $ 101.66 | -7.65 % | $ 5.1 B | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-43.1 | $ 3.63 | 8.36 % | $ 5.98 M | Israel |
 |
Aeterna Zentaris
AEZS
|
4.4 | - | 5.93 % | $ 314 M | Canada |
 |
MannKind Corporation
MNKD
|
34.4 | $ 3.65 | 2.39 % | $ 1.12 B | USA |
 |
Genprex
GNPX
|
-4.81 | $ 0.89 | 0.28 % | $ 830 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-4.27 | - | - | $ 1.01 B | USA |
 |
CureVac N.V.
CVAC
|
-7.74 | - | - | $ 867 M | Germany |
 |
Applied Genetic Technologies Corporation
AGTC
|
0.546 | - | - | $ 26.5 M | USA |
 |
AIkido Pharma
AIKI
|
-45.5 | - | 1.93 % | $ 17.4 M | USA |
 |
Genmab A/S
GMAB
|
2.7 | $ 27.58 | -1.11 % | $ 17 B |  Danmark |
 |
Akero Therapeutics
AKRO
|
-4.64 | - | - | $ 3.67 B | USA |
 |
Matinas BioPharma Holdings
MTNB
|
-8.08 | $ 0.65 | -4.03 % | $ 3.56 M | USA |
 |
Aptose Biosciences
APTO
|
388 | - | -45.71 % | $ 1.2 M | Canada |
 |
Aptinyx
APTX
|
-1.56 | - | -39.0 % | $ 4.57 M | USA |
 |
Akouos
AKUS
|
-1.13 | - | 0.23 % | $ 488 M | USA |
 |
Albireo Pharma
ALBO
|
-3.38 | - | -0.23 % | $ 916 M | USA |
 |
Nanobiotix S.A.
NBTX
|
-4.62 K | $ 42.53 | 1.6 % | $ 286 B | France |
 |
Allakos
ALLK
|
-1.56 | - | - | $ 28.6 M | USA |
 |
AlloVir
ALVR
|
-3.61 | - | 4.14 % | $ 49.1 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
-316 | $ 22.31 | -7.72 % | $ 2.84 B | USA |
 |
Allena Pharmaceuticals
ALNA
|
0.298 | - | 3.16 % | $ 1.9 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
-20.4 | - | -11.43 % | $ 502 K | USA |
|
Applied Molecular Transport
AMTI
|
-1.19 | - | - | $ 10.1 M | USA |
 |
Alpine Immune Sciences
ALPN
|
-5.5 | - | - | $ 2.17 B | USA |
 |
Aileron Therapeutics
ALRN
|
-0.0369 | - | 10.36 % | $ 9.8 M | USA |